Therefore, our study highlights eK8 as a promising accessible and actionable therapeutic target for the management of aggressive colorectal tumors, such as those resistant to EGFR inhibition due to their KRAS-mutated status. This evidence concerns the gene EPHA4 and colorectal neoplasm.